GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Dextromethorphan / bupropion - AUVELITY extended-release tablets

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug2 sources available - open source summaries, references and comparisons

AUVELITY / dextromethorphan bupropion

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

A newer indication changes the renal initiation schedule

The May 2024 mirror addresses MDD. The August 2026 official label includes a separate lower-strength starting schedule for Alzheimer-dementia-associated agitation in moderate impairment.

Before applying: Confirm indication and the exact combination strength. Read the official indication-specific renal subsection rather than importing general twice-daily titration.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

DailyMed / AUVELITY exact product label

Product / population
AUVELITY extended-release combination tablets. The May 2024 mirror covers MDD; the separately retrieved August 2026 official label also includes agitation associated with dementia due to Alzheimer disease.
Renal measure
eGFR, mL/min/1.73 m2

Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.

No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.

Renal dosing, restrictions and evidence limits

At eGFR 30-59 mL/min/1.73 m2, the MDD starting and maximum dosage is 45 mg dextromethorphan hydrobromide / 105 mg bupropion hydrochloride once each morning.

For agitation associated with dementia due to Alzheimer disease in the same renal band, start 30 mg/105 mg each morning; on Day 8, increase to 45 mg/105 mg each morning based on tolerability. That is the maximum renal dosage. Severe impairment, eGFR 15-29, is not recommended; no below-15 or dialysis schedule is established by the selected instructions.

Confirm indication, strength and renal band before titration. Assess blood pressure before treatment and periodically, and screen for other dextromethorphan- or bupropion-containing products.

Source revision: 8/2026 | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

DailyMed / AUVELITY exact product label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

AUVELITY extended-release combination tablets. The May 2024 mirror covers MDD; the separately retrieved August 2026 official label also includes agitation associated with dementia due to Alzheimer disease.

Renal method: eGFR, mL/min/1.73 m2
Retrieved: 2026-09-09

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - AUVELITY

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

AUVELITY extended-release combination tablets. The May 2024 mirror covers MDD; the separately retrieved August 2026 official label also includes agitation associated with dementia due to Alzheimer disease.

Renal method: eGFR, mL/min/1.73 m2
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

A newer indication changes the renal initiation schedule

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

label version and indication

A newer indication changes the renal initiation schedule

The May 2024 mirror addresses MDD. The August 2026 official label includes a separate lower-strength starting schedule for Alzheimer-dementia-associated agitation in moderate impairment.

How to use this: Confirm indication and the exact combination strength. Read the official indication-specific renal subsection rather than importing general twice-daily titration.

GlobalRPh RX List - AUVELITYDailyMed / AUVELITY exact product label

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDailyMed / AUVELITY exact product labelGlobalRPh RX List - AUVELITY
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/auvelity-drug/

Exact product and population

AUVELITY extended-release combination tablets. The May 2024 mirror covers MDD; the separately retrieved August 2026 official label also includes agitation associated with dementia due to Alzheimer disease.

RDM55-SCOPE-dextromethorphan-bupropion-auvelity · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

DailyMed / AUVELITY exact product label

Open original reference

Open / share this exact local source

DailyMed / Axsome Therapeutics, Inc. · AUVELITY extended-release combination tablets. The May 2024 mirror covers MDD; the separately retrieved August 2026 official label also includes agitation associated with dementia due to Alzheimer disease.

Renal method: eGFR, mL/min/1.73 m2
Source date: 8/2026
Retrieved: 2026-09-09

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At eGFR 30-59 mL/min/1.73 m2, the MDD starting and maximum dosage is 45 mg dextromethorphan hydrobromide / 105 mg bupropion hydrochloride once each morning.

For agitation associated with dementia due to Alzheimer disease in the same renal band, start 30 mg/105 mg each morning; on Day 8, increase to 45 mg/105 mg each morning based on tolerability. That is the maximum renal dosage. Severe impairment, eGFR 15-29, is not recommended; no below-15 or dialysis schedule is established by the selected instructions.

Confirm indication, strength and renal band before titration. Assess blood pressure before treatment and periodically, and screen for other dextromethorphan- or bupropion-containing products.

RDM55-official-dextromethorphan-bupropion-auvelity-b2d5ea1913-C1 · Source locator: Sections 1, 2.1, 2.4 and 8.6

Source-specific limits

Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.

No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dcefda7c-9a68-278e-e053-2995a90aec79
Retrieved
2026-09-09
Exact label title
AUVELITY - dextromethorphan hydrobromide, bupropion hydrochloride tablet, multilayer, extended release; AUVELITY kit
DailyMed Set ID
dcefda7c-9a68-278e-e053-2995a90aec79
Labeler
Axsome Therapeutics, Inc.
DailyMed page updated
2026-08-17
Label revision
8/2026
Renal-function method
eGFR, mL/min/1.73 m2
Source date/version
8/2026
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
fc84850c4e0d7021ef4ead23a496d593e19dac9e4b7a6ba5fffa26496292b5c7
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - AUVELITY

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · AUVELITY extended-release combination tablets. The May 2024 mirror covers MDD; the separately retrieved August 2026 official label also includes agitation associated with dementia due to Alzheimer disease.

Renal method: eGFR, mL/min/1.73 m2
Source date: 5/2024
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For MDD with moderate impairment, indexed eGFR 30-59 mL/min/1.73 m2, the selected May 2024 mirror specifies one 45 mg dextromethorphan hydrobromide / 105 mg bupropion hydrochloride tablet each morning. Severe impairment, eGFR 15-29, is not recommended.

This older MDD-only source does not supply the newer indication-specific initiation schedule. Do not substitute the usual twice-daily titration or treat an unspecified tablet strength as interchangeable. No regimen below eGFR 15 or during dialysis is supplied by this extract.

RDM55-rxlist-dextromethorphan-bupropion-auvelity-b9ee4e8822-C1 · Source locator: Renal Impairment; selected Dosage, Pharmacokinetics and Warnings sections

Source-specific limits

Selected sections only. A hosted mirror is not independent confirmation of the underlying label.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/auvelity-drug/
Retrieved
2026-09-09
Renal-function method
eGFR, mL/min/1.73 m2
Source date/version
5/2024
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
00e3c03b413df981349cd73a45c92a4fcf5530094211dda571b9278a95cec5a4

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/auvelity-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
d4500b48b9ff7578896da2ceed7144d660e75587fdc3e59738715fdd0d8cb547
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report